Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Prostate
    November 2025
  1. PEINADO BRR, Nazario RMF, Frazao DR, Ne YGS, et al
    Is There Any Association Between Periodontitis and Prostatic Alterations? A Systematic Review.
    Prostate. 2025;85:1369-1385.
    >> Share

  2. SANDOVAL V, Osinski T, Malshy K, Feng C, et al
    Long-Term Oncological Outcomes of Robot-Assisted Radical Prostatectomy for Clinically Localized Grade Groups 4 and 5 Prostate Cancers Diagnosed on Prostate Biopsy.
    Prostate. 2025;85:1432-1439.
    >> Share

    October 2025
  3. KIDD M, Rempega G, Kepinski M, Slomian S, et al
    Utility of the PROSTest, a Novel Blood-Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease.
    Prostate. 2025 Oct 23. doi: 10.1002/pros.70086.
    >> Share

  4. KAWAI T, Maki K, Taguchi S, Fujii Y, et al
    Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration-Resistant Prostate Cancer.
    Prostate. 2025 Oct 21. doi: 10.1002/pros.70082.
    >> Share

  5. WHYNE EZ, Choi SH, Unni N, Kanjwal S, et al
    Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core.
    Prostate. 2025 Oct 8. doi: 10.1002/pros.70074.
    >> Share

  6. LIU Y, Wang H, Wang Z, Wang J, et al
    The Infiltration of IL-18-Related Immune Cells and Their Bidirectional Regulatory Roles in the Pathogenesis of Prostate Cancer.
    Prostate. 2025 Oct 7. doi: 10.1002/pros.70077.
    >> Share

  7. MULCRONE J, Noakes J, Braunagel T, Hankins-Chace K, et al
    Lessons Learned From a Mindfulness Intervention Study in Men With Newly Diagnosed Prostate Cancer.
    Prostate. 2025 Oct 7. doi: 10.1002/pros.70076.
    >> Share

  8. MADENDERE S, Esen B, Karaarslan UC, Muduroglu M, et al
    Are NCCN and EAU Active Surveillance Criteria Reliable in Patients With ISUP Grade-2 Intermediate-Risk Prostate Cancer? A Novel Model Integrating MRI to Predict Adverse Pathology.
    Prostate. 2025 Oct 6. doi: 10.1002/pros.70073.
    >> Share

  9. TILLU N, Schussel K, P Kolanukuduru K, Choudhary M, et al
    Diagnostic Utility of 18F-DCFPyL PSMA PET/CT-Ultrasound Fusion Biopsies Across the Prostate Cancer Spectrum.
    Prostate. 2025 Oct 6. doi: 10.1002/pros.70068.
    >> Share

  10. NAKAI Y, Onishi K, Asakawa I, Miyake M, et al
    Evaluating Local Doses for Prostate Cancer Treatment Using Low-Dose-Rate Brachytherapy Considering Oncological Control and Toxicity.
    Prostate. 2025 Oct 6. doi: 10.1002/pros.70039.
    >> Share

  11. ROSALES RDR, Venkatesh A, Kanumuambidi JP, Ishiyama Y, et al
    Genetics-Driven, Intensity-Modulated Adaptive Management of Patients With Metastatic Prostate Cancer.
    Prostate. 2025 Oct 5. doi: 10.1002/pros.70070.
    >> Share

  12. SHARMA R, Ozawa Y, Moschovas MC, Saikali S, et al
    Impact of Intraoperative Enlarged Median Lobe on Functional Recovery Following Robot-Assisted Radical Prostatectomy: A Retrospective Cohort Analysis.
    Prostate. 2025;85:1342-1351.
    >> Share

  13. WENZEL M, Nathan A, Covas Moschovas M, Wagner C, et al
    Oncological Outcomes After Robotic Salvage Radical Prostatectomy in Patients Primarily Treated With Focal Versus Radiation Therapy: A Junior ERUS/YAU Collaborative Study.
    Prostate. 2025;85:1332-1341.
    >> Share

  14. CHECK MH, Ernst SE, Sfanos KS
    Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro.
    Prostate. 2025;85:1282-1289.
    >> Share

  15. SAKAMOTO S, Zhao X, Onozawa M, Shiota M, et al
    Impact of Human Development Index Category on Prostate Cancer Characteristics in Asia.
    Prostate. 2025 Oct 1. doi: 10.1002/pros.70050.
    >> Share

  16. TANG Z, Guo P, Liu Y
    LIAS Promotes Cuproptosis in Prostate Cancer Cells by Suppressing Glycolysis via the p53 Signaling Pathway.
    Prostate. 2025 Oct 1. doi: 10.1002/pros.70049.
    >> Share

  17. HAN D, Jiang C, Liu H, Ye D, et al
    MEIS2 Modulates Oxidative Phosphorylation and ROS Generation to Affect CD8(+) T Cell Antitumor Immunity in Prostate Cancer.
    Prostate. 2025 Oct 1. doi: 10.1002/pros.70051.
    >> Share

    September 2025
  18. FEDELE N, Wilson RJ, Doherty J, Baxi P, et al
    Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate-Resistant Prostate Cancer.
    Prostate. 2025 Sep 28. doi: 10.1002/pros.70060.
    >> Share

  19. QIONG L, Qingyi L, Bohong G, YouCheng H, et al
    Influence of 5-Alpha Reductase Inhibitors on PI-RADS Scores and Prostate Cancer Detection: A Systematic Review and Meta-Analysis.
    Prostate. 2025 Sep 28. doi: 10.1002/pros.70066.
    >> Share

  20. BORQUE-FERNANDO A, Guerrero-Ochoa P, Esteban LM, Hernandez A, et al
    Integration of Primary Care Into the Follow-Up Protocol for Prostate Cancer Patients in Aragon, Spain. It Is Time to Follow Other Successful Models in the Region.
    Prostate. 2025 Sep 24. doi: 10.1002/pros.70057.
    >> Share

  21. YAZGAN SC, Bolek H, Coskunpinar M, Yekeduz E, et al
    Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration-Sensitive Prostate Cancer.
    Prostate. 2025 Sep 24. doi: 10.1002/pros.70062.
    >> Share

  22. HOGGARD NK, Berg FM, Szczepaniak MR, Wang X, et al
    Pathology of a Canine Model of Localized Prostate Carcinoma.
    Prostate. 2025 Sep 22. doi: 10.1002/pros.70054.
    >> Share

  23. YANEZ-CASTILLO YM, Melgarejo-Segura MT, Arrabal-Polo MA, Jimenez-Pacheco A, et al
    Enhancing Prostate Cancer Diagnosis: The Combined Value of PHI and mpMRI.
    Prostate. 2025 Sep 22. doi: 10.1002/pros.70055.
    >> Share

  24. LI C, He C, Pan J, Feng Y, et al
    MIF Facilitates Resistance to Androgen Deprivation Therapy by Regulating AMPD2 Expression in Prostate Cancer Cells.
    Prostate. 2025 Sep 19. doi: 10.1002/pros.70053.
    >> Share


  25. Correction to "Resveratrol Inhibits the Tumor Migration and Invasion by Upregulating TET1 and Reducing TIMP2/3 Methylation In Prostate Carcinoma Cells".
    Prostate. 2025 Sep 14. doi: 10.1002/pros.70047.
    >> Share

  26. FALKENBACH F, Di Bello F, Penaranda NR, Longoni M, et al
    USPSTF Recommendation Against PSA Screening vs. Stage and Cancer-Specific Mortality in Localized Prostate Cancer.
    Prostate. 2025 Sep 9. doi: 10.1002/pros.70045.
    >> Share

  27. HUNT TC, Malshy K, Steidle M, Li A, et al
    Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized Prostate Cancer.
    Prostate. 2025 Sep 9. doi: 10.1002/pros.70043.
    >> Share

  28. MARTINEZ OSORIO CA, Sopena Sutil R, Vilaseca Cabo A, Linares Espinos E, et al
    Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide.
    Prostate. 2025 Sep 4. doi: 10.1002/pros.70040.
    >> Share

  29. MICHAEL J, Li EV, Huang M, Handa N, et al
    Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance.
    Prostate. 2025;85:1114-1120.
    >> Share

  30. YUKIHIRO K, Sekino Y, Kobayashi G, Hatayama T, et al
    Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment.
    Prostate. 2025 Sep 1. doi: 10.1002/pros.70042.
    >> Share

    August 2025
  31. GATENBY RA, Anderson ARA, Brown JS, Gallaher J, et al
    Directed Evolution Restored Castrate Sensitivity in a Patient With Castrate Resistant Metastatic Prostate Cancer.
    Prostate. 2025 Aug 28. doi: 10.1002/pros.70038.
    >> Share

  32. KURUCZ LM, Natali T, Westerhout S, Hagens M, et al
    Prostate Volume and PSA-Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics.
    Prostate. 2025 Aug 18. doi: 10.1002/pros.70036.
    >> Share

  33. PAVLOVICH CP, Wei J, Gielzak M, Shi Z, et al
    Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes.
    Prostate. 2025 Aug 18. doi: 10.1002/pros.70037.
    >> Share

  34. XU K, Khan A, Evancho P, Chu M, et al
    Analysis of the Increased Incidence of Aggressive Prostate Cancer After Prior Testicular Cancer.
    Prostate. 2025 Aug 16. doi: 10.1002/pros.70035.
    >> Share

  35. THILLAINADESAN G, Amemiya Y, Nam R, Seth A, et al
    Machine Learning Approach Identifies miRNA Biomarkers for Post Surgical Patient Stratification in Prostate Cancer.
    Prostate. 2025 Aug 16. doi: 10.1002/pros.70034.
    >> Share

  36. YILMAZ AB
    Letter to the Editor: "Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms".
    Prostate. 2025 Aug 13. doi: 10.1002/pros.70012.
    >> Share


  37. Erratum to "Inhibition of Signaling Downstream of Beta-2 Adrenoceptor by Propranolol in Prostate Cancer Cells".
    Prostate. 2025 Aug 13. doi: 10.1002/pros.70033.
    >> Share

  38. BERTINI A, Stephens A, Finocchiaro A, Vigano S, et al
    Mortality and Additional Treatment Rates in Pathologically High-Risk Prostate Cancer With Prostate-Specific Antigen Persistence at Robot-Assisted Radical Prostatectomy: Long-Term Report From Single Tertiary Referral Center.
    Prostate. 2025 Aug 10. doi: 10.1002/pros.70031.
    >> Share

  39. CASTILLO LC, Belenchon IR, Sanz IP, Marenco RS, et al
    Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence.
    Prostate. 2025;85:1016-1023.
    >> Share

  40. BERTINI A, Stephens A, Finocchiaro A, Silvia V, et al
    Association of Area of Deprivation Index With Active Surveillance (AS) Utilization and Adherence to as Guidelines: Results From a Contemporary North American Cohort.
    Prostate. 2025;85:1024-1035.
    >> Share

    July 2025
  41. LEE IT, Hou CM, Vo TTT, Hong JH, et al
    Optimizing Prostate Cancer Care: Clinical Utility of the Prostate Health Index.
    Prostate. 2025 Jul 31. doi: 10.1002/pros.70025.
    >> Share

  42. ZURL H, Pohl KK, Korn SM, Piccolini A, et al
    Racial Disparities in the Use of MRI and PET Scan Among Medicare Beneficiaries With Prostate Cancer.
    Prostate. 2025 Jul 29. doi: 10.1002/pros.70022.
    >> Share

  43. GOUVEIA A, Dayes I, Tsakiridis T
    In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.
    Prostate. 2025 Jul 28. doi: 10.1002/pros.70023.
    >> Share

  44. REIJNEN C, Heemsbergen WD, Wever KE, Panneflek A, et al
    Efficacy of Treatments for T3bN0M0 Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
    Prostate. 2025 Jul 28. doi: 10.1002/pros.70024.
    >> Share

  45. MIYAHIRA AK, Soule HR
    The 31st Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2025 Jul 27. doi: 10.1002/pros.70015.
    >> Share

  46. FUJIMOTO S, Morita T, Yamamoto Y, Saruta M, et al
    Prognostic Impact of Initial Prostate-Specific Antigen in Metastatic Hormone-Sensitive Prostate Cancer Patients With Extensive Bone Metastases Under Androgen Receptor Signaling Inhibitor.
    Prostate. 2025 Jul 27. doi: 10.1002/pros.70017.
    >> Share

  47. NAZARI V, Keshavarzian O, Pasalar M, Ghasemi S, et al
    Evaluating the Efficacy of Barley Water in Alleviating Radiotherapy-Induced Dysuria in Prostate Cancer Patients: A Randomized Placebo-Controlled Trial.
    Prostate. 2025 Jul 23. doi: 10.1002/pros.70008.
    >> Share

  48. CHAN E, Pugh SL, Simko JP, Feng F, et al
    Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy.
    Prostate. 2025 Jul 21. doi: 10.1002/pros.70018.
    >> Share

  49. TOKUNAGA T, Kobayashi K, Nagao K, Fujikawa K, et al
    Refining the CHAARTED Classification: Clinical Utility of a Novel Integrated Risk Stratification Model Incorporating Gleason Grade and Biochemical Markers in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    Prostate. 2025 Jul 21. doi: 10.1002/pros.70019.
    >> Share

  50. NAM HS, Asberry AM, Deng X, Liu S, et al
    PRMT5:MEP50 Are Mediators of Treatment-Induced Neuroendocrine Differentiation in Prostate Cancer.
    Prostate. 2025 Jul 17. doi: 10.1002/pros.70006.
    >> Share

  51. KOISTINEN H, Merivirta RM, Lehto TP, Lempiainen A, et al
    Altered Glycosylation of PSA in Prostate Cancer Tissue.
    Prostate. 2025 Jul 9. doi: 10.1002/pros.70014.
    >> Share

  52. VERMA S, Thompson CL, Fu P, MacLennan GT, et al
    miRNAs Regulating GSTP1 as Potential Diagnostic Biomarkers in Prostate Cancer.
    Prostate. 2025 Jul 9. doi: 10.1002/pros.70011.
    >> Share

  53. HASHIZUME A, Kawahara T, Ito Y, Uemura K, et al
    Comparative Effectiveness of First-Line Treatments for Castration-Resistant Prostate Cancer: A Large-Scale Retrospective Study in Japan.
    Prostate. 2025 Jul 9. doi: 10.1002/pros.70005.
    >> Share

  54. OZAKI K, Yoneyama T, Kubota Y, Yoneyama MS, et al
    Annexin A1-Targeted d-Peptide-Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer.
    Prostate. 2025 Jul 6. doi: 10.1002/pros.70007.
    >> Share

  55. SUNDARESAN I, Palanisamy N, Saraswathy R
    Exploring Latent Prostate Cancer: A Forensic Autopsy Study in South India.
    Prostate. 2025 Jul 6. doi: 10.1002/pros.70010.
    >> Share

  56. SHARIFI MN, Heninger E, Bootsma ML, Recchia EE, et al
    Transcriptomic Signatures of Monocyte-Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer.
    Prostate. 2025 Jul 2. doi: 10.1002/pros.70000.
    >> Share

    June 2025
  57. GRUBER I, Koelbl O, Meier MM
    Late Bowel Symptoms in Long-Term Survivors of Prostate Cancer Following Radiotherapy.
    Prostate. 2025 Jun 24. doi: 10.1002/pros.70004.
    >> Share

  58. GRUTMAN AJ, Jing Y, Ng DK, Landis PK, et al
    History of Vasectomy Is not Associated With Prostate Cancer Progression in Men on Active Surveillance.
    Prostate. 2025 Jun 23. doi: 10.1002/pros.70001.
    >> Share

  59. TAKAHASHI T
    Evidence and Rationale for Prostate Cancer Screening.
    Prostate. 2025 Jun 22. doi: 10.1002/pros.70002.
    >> Share

  60. LEMSTER AL, Grunhagen S, Schmalfeld S, Lenz F, et al
    Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer.
    Prostate. 2025 Jun 12. doi: 10.1002/pros.24925.
    >> Share

  61. YANG YJ, Zeng C, Schaffer KR, Tran TC, et al
    Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort.
    Prostate. 2025 Jun 11. doi: 10.1002/pros.24913.
    >> Share

  62. FUKUSHIMA T, Goto K, Nakano Y, Tasaka S, et al
    Comprehensive Genomic Profiling Testing for Castration-Resistant Prostate Cancer in Advanced Elderly Patients: A Single-Center Retrospective Cohort Study.
    Prostate. 2025 Jun 10. doi: 10.1002/pros.24926.
    >> Share

  63. HORVATH A, Blasszauer C, Komka I, Reibl D, et al
    Real-World Overall Survival Comparison of Enzalutamide and Abiraterone In First- and Second-Line Setting of Metastatic Castration-Resistant Prostate Cancer.
    Prostate. 2025 Jun 8. doi: 10.1002/pros.24923.
    >> Share

  64. XUE C, Ko HK, Shi K, Pittsenbarger J, et al
    Understanding Enzalutamide-Resistance Based on a Functional Single-Cell Approach.
    Prostate. 2025;85:888-899.
    >> Share

  65. MIURA Y, Yoneyama T, Yamamoto H, Suzuki H, et al
    Analytical and Real-World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population.
    Prostate. 2025;85:869-887.
    >> Share

    May 2025
  66. ODERDA M, Orlando G, Calleris G, Capella G, et al
    Role of Cell-Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2-ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance.
    Prostate. 2025 May 29. doi: 10.1002/pros.24921.
    >> Share

  67. YANG P, Yang B
    A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA.
    Prostate. 2025 May 26. doi: 10.1002/pros.24920.
    >> Share

  68. ONAL C, Elmali A, Demirhan B, Guler OC, et al
    SBRT Boost in Prostate Cancer: Progress Made, Questions Remain.
    Prostate. 2025 May 26. doi: 10.1002/pros.24919.
    >> Share

  69. FENG F, Xu Z
    Bimodal Imaging: Detection Rate of Clinically Significant Prostate Cancer Is Higher in MRI Lesions Visible to Transrectal Ultrasound.
    Prostate. 2025 May 23. doi: 10.1002/pros.24839.
    >> Share

  70. XU J, Lu J, Gielzak M, Lilly Zheng S, et al
    Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines.
    Prostate. 2025 May 22. doi: 10.1002/pros.24918.
    >> Share

  71. MIURA H, Hamaya T, Yoneyama T, Shimoyama T, et al
    The Effects of the Blood-Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies.
    Prostate. 2025 May 22. doi: 10.1002/pros.24917.
    >> Share

  72. QU LG, Vaselkiv JB, Perera M, Mucci L, et al
    Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation.
    Prostate. 2025 May 20. doi: 10.1002/pros.24915.
    >> Share

  73. AGUILERA M, Klinkebiel DL, Williams V, Rovatti J, et al
    Altered Ten Eleven Translocation Methylcytosine Dioxygenase Expression and DNA Hydroxymethylation in a Mouse Model of Prostate Cancer.
    Prostate. 2025 May 11. doi: 10.1002/pros.24912.
    >> Share

  74. MANDL A, Zahurak ML, Metri NA, Shore ND, et al
    Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant.
    Prostate. 2025 May 5. doi: 10.1002/pros.24903.
    >> Share

  75. SAPERSTEIN L, Rowe SP, Gorin MA, Pienta KJ, et al
    Impact of Concomitant Hormone Therapy on the Diagnostic Performance of (18)F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B.
    Prostate. 2025 May 4. doi: 10.1002/pros.24909.
    >> Share

  76. RAHBAR K, Kidd M, Prasad V, David Rosin R, et al
    Clinical Sensitivity and Specificity of the PROSTest in an American Cohort.
    Prostate. 2025;85:558-566.
    >> Share

  77. ARRIAGA-IZABAL D, Morales-Lazcano F, Canizalez-Roman A
    Development and Validation of a Predictive Model of Prostate Screening Compliance: A Nationwide Population-Based Study.
    Prostate. 2025;85:513-523.
    >> Share

  78. LIN YH, Lin KJ, Shao IH
    Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in Prostate Cancer.
    Prostate. 2025;85:719-720.
    >> Share

  79. DIEUDONNE ZOJ, Gebreselassie KH, Mohammed TO, Khalid A, et al
    Current Status of Prostate Biopsy in Africa: Are We Ready for a Targeted Biopsy?
    Prostate. 2025;85:638-645.
    >> Share

  80. ASIRI IM, Chen RC, Master V, Mi L, et al
    Thromboembolic Events in Castration-Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors.
    Prostate. 2025 May 1. doi: 10.1002/pros.24902.
    >> Share

    April 2025
  81. GOUVEIA A, Mesci A, Isfahanian N, Dayes I, et al
    Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.
    Prostate. 2025 Apr 27. doi: 10.1002/pros.24905.
    >> Share

  82. BACLE C, Mazancourt ES, Abid N, Ruffion A, et al
    Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms.
    Prostate. 2025 Apr 24. doi: 10.1002/pros.24906.
    >> Share

  83. SRUTHI KK, Ummanni R
    Valosin-Containing Protein (VCP/p97) Mediates Neuroendocrine Differentiation in Prostate Cancer Cells Through Pim1 Signaling Inducing Autophagy.
    Prostate. 2025 Apr 23. doi: 10.1002/pros.24900.
    >> Share

  84. DEE EC, Iyengar R, Narayan A, Feliciano EJG, et al
    National Cancer System Characteristics and Prostate Cancer Outcomes: An Analysis of Global Data.
    Prostate. 2025 Apr 15. doi: 10.1002/pros.24901.
    >> Share

  85. SHIMOMURA T, Urabe F, Muramoto K, Yanagisawa T, et al
    Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort.
    Prostate. 2025 Apr 8. doi: 10.1002/pros.24898.
    >> Share

  86. SHIMOMURA T, Otsuka N, Urabe F, Muramoto K, et al
    PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?
    Prostate. 2025 Apr 6. doi: 10.1002/pros.24885.
    >> Share

  87. OKAMURA T, Izumi K, Kurokawa S, Shima T, et al
    Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study.
    Prostate. 2025 Apr 3. doi: 10.1002/pros.24897.
    >> Share

  88. PAE S, Sakamoto S, Zhao X, Tamura T, et al
    LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy.
    Prostate. 2025 Apr 2. doi: 10.1002/pros.24899.
    >> Share

  89. ZHANG X, Sang W, Hong X, Qu H, et al
    Effect of Dendritic Cells Injection After Radical Prostatectomy on Prostate Cancer in Mice.
    Prostate. 2025 Apr 2. doi: 10.1002/pros.24892.
    >> Share

  90. BARABAN EG, Vlachou E, Patel S, Kates M, et al
    Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study.
    Prostate. 2025;85:443-447.
    >> Share

  91. GAMAL A, Moschovas MC, Jaber AR, Saikali S, et al
    Functional and Oncological Outcomes of Very Large Prostate Sizes Post Robotic Radical Prostatectomy: A Propensity Score-Matched Analysis.
    Prostate. 2025;85:456-462.
    >> Share

  92. TANG L, Wu M, Chen K, Gao F, et al
    Automatic MRI-TRUS Fusion Technique for Transperineal Biopsy Guidance: From Preoperative Planning to Intraoperative Navigation.
    Prostate. 2025;85:424-432.
    >> Share

  93. SRIDHAR S, Abouelfetouh Z, Codreanu I, Gupta N, et al
    The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI-RADS or
    Prostate. 2025;85:413-423.
    >> Share

    March 2025
  94. MANTENA RV, Bhadouriya R, Jain U, Patel TA, et al
    Treatment Noncompletion and Shorter Radiation Regimens Among US Patients With Prostate Cancer: A Focus on Asian American and Pacific Islander Patients.
    Prostate. 2025 Mar 31. doi: 10.1002/pros.24887.
    >> Share

  95. VASSALLO R, Mannas MP, Salcudean SE, Black PC, et al
    Developments in Ultrasound-Based Imaging for Prostate Cancer Detection.
    Prostate. 2025 Mar 28. doi: 10.1002/pros.24893.
    >> Share

  96. LOSEE M, Kavanaugh M, Liu M, Borges N, et al
    Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience.
    Prostate. 2025 Mar 18. doi: 10.1002/pros.24880.
    >> Share

  97. NG K, Priyadarshini G, Sarker SJ, Robinson A, et al
    A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate-Resistant Prostate Cancer (TRICREST).
    Prostate. 2025 Mar 18:e24877. doi: 10.1002/pros.24877.
    >> Share

  98. SUZUKI K, Hirata J, Okamura Y, Bando Y, et al
    Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of >/= 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis.
    Prostate. 2025 Mar 16. doi: 10.1002/pros.24889.
    >> Share

  99. MONDIA MWL, Batchala PP, Dreicer R, Devitt ME, et al
    Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review.
    Prostate. 2025 Mar 13. doi: 10.1002/pros.24890.
    >> Share

  100. ONAL C, Guler OC, Erbay G, Demirhan B, et al
    Propensity Score Matched Analysis of External Beam Radiotherapy With or Without Focal Boost to Intraprostatic Lesions in Prostate Cancer.
    Prostate. 2025 Mar 11. doi: 10.1002/pros.24888.
    >> Share

  101. VIGANO S, Finati M, Stephens A, Bertini A, et al
    Socioeconomic Disparities in Prostate Cancer Treatment: The Impact of Area Deprivation Index on Initial Treatment Type for Localized PCa in a North-American Cohort.
    Prostate. 2025 Mar 11:e24882. doi: 10.1002/pros.24882.
    >> Share

  102. CHEN G, Li Y, Geng S, Lv L, et al
    Evaluating the Heterogeneity of Advanced Prostate Cancer by (18)F-DCFPyL and (18)F-FDG PET/CT in a Prospective Cohort.
    Prostate. 2025 Mar 5. doi: 10.1002/pros.24881.
    >> Share

  103. SHI Y, Wei X, Zhao F, Chen J, et al
    The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate.
    Prostate. 2025 Mar 4:e24869. doi: 10.1002/pros.24869.
    >> Share

  104. ROBINSON E, Kinsella N, Ap Dafydd D, Shur J, et al
    Prostate Specific Antigen Density and Clinically-Significant Prostate Cancer: The Influence of Prostatic Volume.
    Prostate. 2025 Mar 3. doi: 10.1002/pros.24886.
    >> Share

  105. ORSINI A, Ferretti S, Porreca A, Castellan P, et al
    PI-RADS in Predicting csPCa: A Comparison Between Academic and Nonacademic Centers.
    Prostate. 2025;85:337-343.
    >> Share

  106. AYRANCI A, Caglar U, Yazili HB, Erdal FS, et al
    PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI-RADS 3 Lesions.
    Prostate. 2025;85:385-390.
    >> Share

  107. ODERDA M, Marquis A, Bertero L, Calleris G, et al
    Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging-Invisible Prostate Cancers: A Matched-Pair Analysis.
    Prostate. 2025;85:374-384.
    >> Share

    February 2025
  108. CHEN H, Pang B, Liu Z, Li B, et al
    The Diagnostic Value of Plasma Small Extracellular Vesicle-Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models.
    Prostate. 2025 Feb 27. doi: 10.1002/pros.24879.
    >> Share

  109. ESEN B, Seymen H, Armutlu A, Koseoglu E, et al
    Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate-Risk Prostate Cancer Patients With Node-Negative PSMA PET.
    Prostate. 2025 Feb 27:e24884. doi: 10.1002/pros.24884.
    >> Share

  110. ESENGUR OT, Stevenson E, Stecko H, Lay NS, et al
    Assessing the Impact of Transition and Peripheral Zone PSA Densities Over Whole-Gland PSA Density for Prostate Cancer Detection on Multiparametric MRI.
    Prostate. 2025 Feb 25:e24863. doi: 10.1002/pros.24863.
    >> Share

  111. HUNT TC, Cheng Z, Li A, Pamatmat AJ, et al
    The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer.
    Prostate. 2025 Feb 24:e24870. doi: 10.1002/pros.24870.
    >> Share

  112. TILKI B, Hurmuz P, Yuce D, Ozyigit G, et al
    Translation, Cross-Cultural Adaptation, and Psychometric Validation of the Turkish Version of the "Expanded Prostate Cancer Index Composite (EPIC)" in Prostate Cancer Patients.
    Prostate. 2025 Feb 23:e24878. doi: 10.1002/pros.24878.
    >> Share


  113. RETRACTION: Stat3 Enhances the Growth of LNCaP Human Prostate Cancer Cells in Intact and Castrated Male Nude Mice.
    Prostate. 2025 Feb 21:e24872. doi: 10.1002/pros.24872.
    >> Share

  114. BRITTON CJ, Andrews JR, Arafa A, Kim Y, et al
    Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single-Institution Pilot Study.
    Prostate. 2025 Feb 20:e24861. doi: 10.1002/pros.24861.
    >> Share

  115. HACIOGLU MB, Kucukarda A, Gokmen I, Gurbuz AF, et al
    Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization.
    Prostate. 2025 Feb 19. doi: 10.1002/pros.24876.
    >> Share

  116. KAMBE T, Kubota M, Yamasaki T, Kawakita M, et al
    Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low-Dose Estramustine in Very High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy.
    Prostate. 2025 Feb 19:e24875. doi: 10.1002/pros.24875.
    >> Share

  117. HABAULT J, Franco JL, Ha S, Schneider JA, et al
    In Vivo Efficacy of a Macrocyclic Peptoid-Peptide Hybrid That Selectively Modulates the Beta-Catenin/TCF Interaction to Inhibit Prostate Cancer.
    Prostate. 2025 Feb 16:e24868. doi: 10.1002/pros.24868.
    >> Share

  118. KAVAK EE, Dilli I
    Progression-Free Survival Prediction Performance of ChatGPT: Analysis With Real Life Data in Early and Locally Advanced Prostate Cancer.
    Prostate. 2025 Feb 13:e24871. doi: 10.1002/pros.24871.
    >> Share

  119. DIAMAND R, Bernard PL, Mjaess G, Benijts J, et al
    Retzius-sparing versus standard robot-assisted laparoscopic prostatectomy: A two-year patient-reported and oncological assessment.
    Prostate. 2025;85:115-122.
    >> Share

  120. CHAI H, Miyasaka Y, Hagiwara Y, Souda H, et al
    Investigation of pelvic floor influence on prostate displacement in image-guided radiotherapy.
    Prostate. 2025;85:123-129.
    >> Share

  121. YANAI Y, Kosaka T, Mikami S, Arai M, et al
    Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy.
    Prostate. 2025;85:308-314.
    >> Share

    January 2025
  122. NISHIMOTO M, De Velasco MA, Yamamoto Y, Fujimoto S, et al
    Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate.
    Prostate. 2025 Jan 31:e24865. doi: 10.1002/pros.24865.
    >> Share

  123. SUN Y, Zhu J, Zhong H, Zhang Z, et al
    Transcriptome-Wide Association Study Identified Novel Blood Tissue Gene Biomarkers for Prostate Cancer Risk.
    Prostate. 2025 Jan 29:e24859. doi: 10.1002/pros.24859.
    >> Share

  124. SHEN C, Chen Z, Hu FH, Wang W, et al
    Reassessing the Role of Low PSA in Prognosis Across Grades of Prostate Cancer: A Cohort Study.
    Prostate. 2025 Jan 29:e24860. doi: 10.1002/pros.24860.
    >> Share

  125. BEATRICI E, De Carne F, Frego N, Moretto S, et al
    Optimizing Prostate Cancer Diagnostic Work-Up Through Micro-Ultrasound: Minimizing Unnecessary Procedures and Reducing Overdiagnoses.
    Prostate. 2025 Jan 28:e24862. doi: 10.1002/pros.24862.
    >> Share

  126. CIRULLI GO, Stephens A, Chiarelli G, Finati M, et al
    Comparing PSA Screening Patterns and Their Role as Predictor of Prostate Cancer Diagnosis: Analysis of a Contemporary North American Cohort.
    Prostate. 2025 Jan 27:e24856. doi: 10.1002/pros.24856.
    >> Share

  127. BESIROGLU H, Kadihasanoglu M
    The Safety and Efficacy of Targeted Alpha Therapy, Ac-225 Prostate-Specific Membrane Antigen, in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
    Prostate. 2025 Jan 26:e24857. doi: 10.1002/pros.24857.
    >> Share

  128. STANGL-KREMSER J, Ricaurte-Fajardo A, Huicochea Castellanos S, Martinez-Fundichely A, et al
    Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis.
    Prostate. 2025 Jan 23:e24853. doi: 10.1002/pros.24853.
    >> Share

  129. UEDA T, Hayakawa K, Horiguchi G, Murashita J, et al
    Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer.
    Prostate. 2025 Jan 15:e24855. doi: 10.1002/pros.24855.
    >> Share

  130. BELKACEMI Y, Coraggio G, Debbi K, Sirmai L, et al
    Relationship Between Radiation Therapy and Fecal Incontinence in Patients Treated for Localized Prostate Cancer: Results of the French ICONES Study.
    Prostate. 2025 Jan 14:e24852. doi: 10.1002/pros.24852.
    >> Share

  131. BAHRI RA, Mohammadi A, Yar EZ, Rezayat M, et al
    Does a Negative Prostate Biopsy Reduce the Risk of Prostate Cancer Reclassification in an Active Surveillance Protocol? An Updated Systematic Review and Meta-Analysis.
    Prostate. 2025 Jan 12:e24851. doi: 10.1002/pros.24851.
    >> Share

  132. KATO H, Goto Y, Kojima S, Onoda Y, et al
    Time to Castration Resistance is Associated With Overall Survival Even After the Achievement of Castration Resistance in Metastatic Prostate Cancer.
    Prostate. 2025 Jan 7:e24850. doi: 10.1002/pros.24850.
    >> Share

  133. ANJALY K, Tiku AB
    Exogenous Treatment of Caffeic Acid and Methylglyoxal Synergistically Enhances Anticancer Effect in Prostate Cancer via Inhibition of Glyoxalase-1.
    Prostate. 2025 Jan 2. doi: 10.1002/pros.24849.
    >> Share

  134. TANG CY, Li JJX, Leung KL, Ma HY, et al
    Is prostatic adenocarcinoma detectable by urine cytology-A multicenter retrospective review.
    Prostate. 2025;85:97-104.
    >> Share

    December 2024
  135. SUZUKI K, Hara T, Watanabe H, Nakane K, et al
    Rapid and Deep Prostate-Specific Antigen Decline is a Prognostic Marker in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Multi-Intuitional Analysis.
    Prostate. 2024 Dec 27. doi: 10.1002/pros.24847.
    >> Share

  136. BARONE B, Amicuzi U, Massanova M, Napolitano L, et al
    The Correlation Between Body Mass Index and Prostate Volume: A Retrospective Analysis of Pre and Postoperative Measurements in Prostate Cancer Patients.
    Prostate. 2024 Dec 23. doi: 10.1002/pros.24845.
    >> Share

  137. ABER ER, Carducci MA, Paller CJ, Denmeade SR, et al
    Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer.
    Prostate. 2024 Dec 22. doi: 10.1002/pros.24841.
    >> Share

  138. YORIOKA MAW, Murta CB, Leite KRM, Cardili L, et al
    ERG and PTEN Role on Active Surveillance for Low-Risk Prostate Cancer in the Multiparametric MRI Era.
    Prostate. 2024 Dec 9:e24835. doi: 10.1002/pros.24835.
    >> Share

  139. CHIARELLI G, Davis M, Stephens A, Finati M, et al
    Racial Disparities in Future Development of Lethal Prostate Cancer Based on Midlife Baseline Prostate-Specific Antigen.
    Prostate. 2024 Dec 9:e24834. doi: 10.1002/pros.24834.
    >> Share

  140. IWAHASHI Y, Wakamiya T, Kawabata H, Deguchi R, et al
    Comparison of Prognosis and Health-Related Quality of Life Between Robot-Assisted Radical Prostatectomy Versus High-Dose-Rate Brachytherapy Combined With External Beam Radiation Therapy and Hormone Therapy for High-Risk Prostate Cancer.
    Prostate. 2024 Dec 5. doi: 10.1002/pros.24831.
    >> Share

  141. OLDAN JD, Rowe SP, Schroeder JA
    Evaluation of online teaching modules for PSMA PET interpretation.
    Prostate. 2024;84:1419-1426.
    >> Share

  142. ONAL C, Elmali A, Erbay G, Demirhan B, et al
    Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients.
    Prostate. 2024 Dec 1. doi: 10.1002/pros.24833.
    >> Share

  143. MIYAHIRA AK, Soule HR, Pienta KJ
    CHARGE: The "Big Questions" in Prostate Cancer for 2024.
    Prostate. 2024 Dec 1. doi: 10.1002/pros.24829.
    >> Share

    November 2024
  144. MIYAHIRA AK, Sharifi M, Chesner LN, El-Kenawi A, et al
    Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2024 Nov 27. doi: 10.1002/pros.24826.
    >> Share

  145. HE E, Li Y, Zhao R, Kong Q, et al
    IL7 as a Risk Factor for Prostate Cancer: Implications for T Cell Apoptosis and Infiltration in the Tumor Microenvironment.
    Prostate. 2024 Nov 26. doi: 10.1002/pros.24830.
    >> Share

  146. GLADIS PUSHPARATHI VP, Justin Xavier D, Chitra P, Kannan G, et al
    Prostate Cancer Classification and Interpretation With Multiparametric Magnetic Resonance Imaging and Gleason Grade Score Using DarkNet53 Model.
    Prostate. 2024 Nov 25:e24827. doi: 10.1002/pros.24827.
    >> Share

  147. NAGASAKA H, Sato S, Suzuki A, Terao H, et al
    Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer.
    Prostate. 2024 Nov 20. doi: 10.1002/pros.24825.
    >> Share


  148. RETRACTION: Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERalpha.
    Prostate. 2024 Nov 17. doi: 10.1002/pros.24822.
    >> Share

  149. JUNIOR EP, Gomes EFDA, de Lima MFR, Raimundo JVS, et al
    Reactive Stroma and Acinar Morphology in Prostate Cancer: Implications for Progression and Prognostic Assessment.
    Prostate. 2024 Nov 13. doi: 10.1002/pros.24824.
    >> Share

  150. BIALAS P, Kobayashi T, Hellsten R, Krzyzanowska A, et al
    pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy.
    Prostate. 2024 Nov 11. doi: 10.1002/pros.24820.
    >> Share

  151. TAKAHASHI T, Nakashima M, Maruno K, Hazama T, et al
    Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI-Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk-Stratification Scoring System.
    Prostate. 2024 Nov 10. doi: 10.1002/pros.24821.
    >> Share

  152. TAO H, Wu F, Li R, Du X, et al
    Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer.
    Prostate. 2024 Nov 3. doi: 10.1002/pros.24817.
    >> Share

  153. ZHAO X, Sakamoto S, Ishikawa H, Yamada Y, et al
    Significant Effect of Carbon-Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High-Risk Prostate Cancer Patients: A Two-Center Controlled Trial Compare With X-Ray External Beam Radiation Therapy.
    Prostate. 2024 Nov 3. doi: 10.1002/pros.24818.
    >> Share

    October 2024
  154. WEI X, Zhao J, Nie L, Shi Y, et al
    Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patients.
    Prostate. 2024 Oct 28. doi: 10.1002/pros.24809.
    >> Share

  155. FINATI M, Morrison C, Stephens A, Chiarelli G, et al
    Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts.
    Prostate. 2024 Oct 28:e24803. doi: 10.1002/pros.24803.
    >> Share

  156. WHYNE EZ, Jeon-Slaughter H, Kelly K, Dowell JE, et al
    Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real-World Retrospective Study.
    Prostate. 2024 Oct 28. doi: 10.1002/pros.24811.
    >> Share

  157. DI BELLO F, Jannello LMI, Baudo A, de Angelis M, et al
    Life Expectancy in High-Grade Incidental Prostate Cancer Patients Versus Population-Based Controls According to Treatment Type.
    Prostate. 2024 Oct 24:e24816. doi: 10.1002/pros.24816.
    >> Share

  158. ERTL IE, Lemberger U, Rajwa P, Petrov P, et al
    Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer.
    Prostate. 2024 Oct 23. doi: 10.1002/pros.24815.
    >> Share

  159. SHUKLA S, Osumi T, Al-Toubat M, Serrano S, et al
    Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased alpha-Catenin.
    Prostate. 2024 Oct 20. doi: 10.1002/pros.24812.
    >> Share

  160. YANAGISAWA T, Fukuokaya W, Hatakeyama S, Narita S, et al
    Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
    Prostate. 2024 Oct 17:e24813. doi: 10.1002/pros.24813.
    >> Share

  161. SEMWAL H, Ladbury C, Sabbagh A, Mohamad O, et al
    Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer.
    Prostate. 2024 Oct 13. doi: 10.1002/pros.24793.
    >> Share

  162. FALKENBACH F, Schmalhofer ML, Tian Z, Mazzucato G, et al
    Size and SUV(max) define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer.
    Prostate. 2024 Oct 9. doi: 10.1002/pros.24806.
    >> Share

  163. TSAI K, Xu P, Guo J, Dean N, et al
    Do Prostate Imaging-Reporting and Data System (PIRADS) lesions predict holmium laser enucleation of prostate outcomes?
    Prostate. 2024;84:1344-1351.
    >> Share

    September 2024
  164. DINCKAL M, Ergun KE, Kalemci MS, Guler E, et al
    Head-to-head comparison of GA-68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer.
    Prostate. 2024 Sep 30. doi: 10.1002/pros.24799.
    >> Share

  165. NARITA S, Yanagisawa T, Hatakeyama S, Hata K, et al
    Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.
    Prostate. 2024 Sep 30. doi: 10.1002/pros.24802.
    >> Share

  166. YAZGAN SC, Yekeduz E, Araz M, Bolek H, et al
    The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 ((177)Lu)-PSMA-617.
    Prostate. 2024 Sep 29. doi: 10.1002/pros.24804.
    >> Share

  167. JIRASKO M, Vitak R, Pecen L, Pinkeova A, et al
    Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy.
    Prostate. 2024 Sep 27. doi: 10.1002/pros.24801.
    >> Share

  168. MURTA CB, Junior JP, de Souza Filho PHF, de Godoy Junior PC, et al
    Prostate cancer focal therapy: surgeon experience influences oncological results.
    Prostate. 2024 Sep 26. doi: 10.1002/pros.24800.
    >> Share

  169. TRAN EU, Ovruchesky E, Yamamoto K, Marley S, et al
    Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series.
    Prostate. 2024 Sep 22. doi: 10.1002/pros.24798.
    >> Share

  170. TANAKA N, Izumi K, Nakai Y, Shima T, et al
    Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.
    Prostate. 2024 Sep 20. doi: 10.1002/pros.24796.
    >> Share

  171. WONG CH, Ko IC, Leung DK, Siu B, et al
    Deep PSA response and extended time-to-nadir as robust predictors of survival in Asian patients with de novo metastatic hormone-sensitive prostate cancer receiving upfront intensified treatment.
    Prostate. 2024 Sep 19. doi: 10.1002/pros.24797.
    >> Share

  172. DE JESUS GNC, Pereira V, Karak P, Shearier E, et al
    A single-center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones.
    Prostate. 2024 Sep 18. doi: 10.1002/pros.24795.
    >> Share

  173. UEKI H, Jimbo N, Terakawa T, Hara T, et al
    Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.
    Prostate. 2024 Sep 15. doi: 10.1002/pros.24791.
    >> Share

  174. KATO T, Sugihara E, Hata Y, Kawakami K, et al
    Diagnostic potential of SDHB mRNA contained in serum extracellular vesicles among patients with prostate cancer.
    Prostate. 2024 Sep 15. doi: 10.1002/pros.24792.
    >> Share

  175. LIU X, Zhu J, Shi MQ, Pan YS, et al
    Predicting clinically significant prostate cancer in elderly patients: A nomogram approach with shear wave elastography.
    Prostate. 2024 Sep 12. doi: 10.1002/pros.24789.
    >> Share

  176. BOIARSKY D, Tewari AK, Gulhan DC, Bakouny Z, et al
    A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.
    Prostate. 2024 Sep 9. doi: 10.1002/pros.24788.
    >> Share

  177. MATRONE F, Del Ben F, Montico M, Muraro E, et al
    Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy.
    Prostate. 2024 Sep 6. doi: 10.1002/pros.24787.
    >> Share

  178. HIMMELSBACH R, Hacklander A, Weishaar M, Morlock J, et al
    Retrospective analysis of the learning curve in perineal robot-assisted prostate biopsy.
    Prostate. 2024;84:1165-1172.
    >> Share

  179. OZKAYA M, Simsekoglu MF, Kalender G, Sahin KC, et al
    Clinical and histopathological parameters in transrectal ultrasound-guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups.
    Prostate. 2024;84:1146-1156.
    >> Share

  180. BARRIERE H, Kaulanjan K, Stempfer G, Mollard P, et al
    Overall and metastasis-free survival of Afro-Caribbean patients with biochemical recurrence after radical prostatectomy.
    Prostate. 2024;84:1112-1118.
    >> Share

  181. WEI Y, Wang H, Xie D, Lu J, et al
    Analysis of three primary prostatic sarcoma cases and literature review.
    Prostate. 2024;84:1218-1223.
    >> Share

  182. CHEN VS, James C, Khemmani M, Desai S, et al
    A prospective evaluation of the prostate microbiome in malignant and benign tissue using transperineal biopsy.
    Prostate. 2024;84:1251-1261.
    >> Share

  183. ADAMS ES, Deivasigamani S, Kotamarti S, Wolf S, et al
    Image-guided multiparametric magnetic resonance imaging-transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, complication and functional outcomes.
    Prostate. 2024;84:1224-1233.
    >> Share

  184. MADENDERE S, Kilic M, Zoroglu H, Sarikaya AF, et al
    Natural history of histologically benign PIRADS 4-5 lesions in multiparametric MRI: Real-life experience in an academic center.
    Prostate. 2024;84:1262-1267.
    >> Share

  185. FALKENBACH F, Ahmad-Sterkau F, Kachanov M, Beyersdorff D, et al
    Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound.
    Prostate. 2024 Sep 1. doi: 10.1002/pros.24785.
    >> Share

  186. LU S, Lamba M, Wang J, Dong Z, et al
    Targeting proliferating cell nuclear antigen enhances ionizing radiation-induced cytotoxicity in prostate cancer cells.
    Prostate. 2024 Sep 1. doi: 10.1002/pros.24786.
    >> Share

    August 2024
  187. TANEGASHIMA T, Shiota M, Eto M
    Reply to Letter to the Editor on "Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients".
    Prostate. 2024 Aug 21. doi: 10.1002/pros.24784.
    >> Share

  188. WANG J, Lao Y, Guan X, Li Z, et al
    Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
    Prostate. 2024 Aug 21. doi: 10.1002/pros.24671.
    >> Share

  189. SAHEB SHARIF-ASKARI F, Al-Shahrabi R, Al Shareef Z
    Response to the letter to the editor: Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
    Prostate. 2024 Aug 21. doi: 10.1002/pros.24779.
    >> Share

  190. SWAMI U, Xie B, Young C, Ramaswamy K, et al
    Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer.
    Prostate. 2024 Aug 20. doi: 10.1002/pros.24777.
    >> Share

  191. LI EV, Lee MS, Guo J, Dean N, et al
    Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate.
    Prostate. 2024 Aug 18. doi: 10.1002/pros.24781.
    >> Share

  192. HSIEH CL, Do AD, Hsueh CY, Raboshakga MO, et al
    L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells.
    Prostate. 2024 Aug 18. doi: 10.1002/pros.24782.
    >> Share

  193. LIU T, Joshu CE, Lu J, Prizment A, et al
    Validation of candidate protein biomarkers previously identified by genetic instruments for prostate cancer risk: A prospective cohort analysis of directly measured protein levels in the ARIC study.
    Prostate. 2024 Aug 15. doi: 10.1002/pros.24774.
    >> Share

  194. WANG H, He K, Liu Y, Yang L, et al
    Expression and immune infiltration studies of IL-33-ST2-NF-kappaB signaling pathway in prostate cancer.
    Prostate. 2024 Aug 7. doi: 10.1002/pros.24778.
    >> Share

  195. WAKAMORI C, De Velasco MA, Sakai K, Kura Y, et al
    A cross-species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk.
    Prostate. 2024 Aug 7. doi: 10.1002/pros.24776.
    >> Share

  196. ONAL C, Guler OC, Torun N, Elmali A, et al
    Impact of definitive radiotherapy on metabolic response measured with (68)Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer.
    Prostate. 2024 Aug 6. doi: 10.1002/pros.24775.
    >> Share

  197. GREENLAND NY, Cooperberg MR, Carroll PR, Cowan JE, et al
    Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification.
    Prostate. 2024;84:1076-1085.
    >> Share

  198. PETERS DE, Brownlee M, Layne-Colon D, Slusher BS, et al
    Discovery of PSMA in the prostate of the common marmoset (Callithrix jacchus).
    Prostate. 2024;84:1086-1088.
    >> Share

    July 2024
  199. SCHMIT S, Malshy K, Ochsner A, Golijanin B, et al
    Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing.
    Prostate. 2024 Jul 25. doi: 10.1002/pros.24772.
    >> Share

  200. FRIEDRICH NA, Gu L, Waller J, De Hoedt AM, et al
    Real-world evidence of (18)F-fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System.
    Prostate. 2024 Jul 19. doi: 10.1002/pros.24770.
    >> Share

  201. MIYAHIRA AK, Soule HR
    The 30th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2024 Jul 17. doi: 10.1002/pros.24768.
    >> Share

  202. SUTERA P, Kim J, Kumar R, Deek RA, et al
    PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.
    Prostate. 2024 Jul 17. doi: 10.1002/pros.24765.
    >> Share

  203. TANEGASHIMA T, Shiota M, Tsukahara S, Mutaguch J, et al
    Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients.
    Prostate. 2024 Jul 10. doi: 10.1002/pros.24769.
    >> Share

  204. WENZEL M, Wagner N, Hoeh B, Siech C, et al
    Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer.
    Prostate. 2024 Jul 10. doi: 10.1002/pros.24767.
    >> Share

  205. JASMINE S, Mandl A, Krueger TEG, Dalrymple SL, et al
    Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
    Prostate. 2024;84:909-921.
    >> Share

    June 2024
  206. KAYAR R, Tokuc E, Ozsoy E, Demir S, et al
    The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI-RADS 3 lesions on multiparametric magnetic resonance imaging.
    Prostate. 2024 Jun 26. doi: 10.1002/pros.24762.
    >> Share

  207. MASSANOVA M, Barone B, Caputo VF, Napolitano L, et al
    The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study.
    Prostate. 2024 Jun 25. doi: 10.1002/pros.24761.
    >> Share

  208. PRAKASH P, Verma S, Gupta S
    Influence of microbiome in intraprostatic inflammation and prostate cancer.
    Prostate. 2024 Jun 20. doi: 10.1002/pros.24756.
    >> Share

  209. MALSHY K, Ochsner A, Homer A, Allu S, et al
    Consistent predictive ability of prostate-specific antigen density prediction model for clinically significant prostate cancer across age strata.
    Prostate. 2024 Jun 20. doi: 10.1002/pros.24757.
    >> Share

  210. CORDOBA SANCHEZ J, Monge-Escartin I, Gil J, Carrera C, et al
    Real-world study: Impact of multidisciplinary management of apalutamide-associated adverse events in prostate cancer.
    Prostate. 2024 Jun 18. doi: 10.1002/pros.24755.
    >> Share

  211. ABRAMOVIC I, Pezelj I, Dumbovic L, Skara Abramovic L, et al
    LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA.
    Prostate. 2024 Jun 2. doi: 10.1002/pros.24749.
    >> Share

  212. DONG Q, Wang C, Shen D, Ma Y, et al
    Combination of prostate volume and apparent diffusion coefficient can stratify patients with a PI-RADS score of 3 to reduce unnecessary prostate biopsies.
    Prostate. 2024;84:780-787.
    >> Share

  213. BUTTNER T, Gartner F, Essler M, Weiten R, et al
    Key learnings from concordant systematic biopsies in prostate-specific membrane antigen positron emission tomography/computed tomography-guided prostate biopsies: Enhancing targeting accuracy.
    Prostate. 2024;84:772-779.
    >> Share

  214. FLETCHER SA, Mamawala MM, Holler AE, Bhanji Y, et al
    Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era.
    Prostate. 2024;84:723-730.
    >> Share

  215. BENNETT R 4TH, Li EV, Ho AY, Aguiar JA, et al
    Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system.
    Prostate. 2024;84:717-722.
    >> Share

  216. CHECCUCCI E, De Cillis S, Alladio E, Piramide F, et al
    Ten-year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot-assisted radical prostatectomy.
    Prostate. 2024;84:832-841.
    >> Share

    May 2024
  217. WENZEL M, Hoeh B, Hurst F, Koll F, et al
    Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients.
    Prostate. 2024 May 29. doi: 10.1002/pros.24754.
    >> Share

  218. TOUMA N, Larose M, Ouellet J, Bedard-Tremblay D, et al
    External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high-grade prostate cancer patients.
    Prostate. 2024 May 27. doi: 10.1002/pros.24742.
    >> Share

  219. TIRUYE T, Roder D, FitzGerald LM, O'Callaghan M, et al
    Impact of comorbidities on prostate cancer-specific mortality: A population-based cohort study.
    Prostate. 2024 May 26. doi: 10.1002/pros.24750.
    >> Share

  220. FERRO M, Crocetto F, La Civita E, Fiorenza M, et al
    Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
    Prostate. 2024 May 26. doi: 10.1002/pros.24752.
    >> Share

  221. ABEDALI Z, Woloshuk A, Cary C, Boris RS, et al
    Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer.
    Prostate. 2024 May 16. doi: 10.1002/pros.24743.
    >> Share

  222. BUTTNER T, Klumper N, Weiten R, Lossin P, et al
    Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer.
    Prostate. 2024 May 15. doi: 10.1002/pros.24747.
    >> Share

  223. NAKAI Y, Tanaka N, Asakawa I, Ohnishi K, et al
    Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matching.
    Prostate. 2024 May 12. doi: 10.1002/pros.24744.
    >> Share

  224. MACKAY S, Oduor IO, Burch TC, Main BP, et al
    Increased alpha2,3-sialyl N-glycosylated prostate-specific membrane antigen (PSMA) in post-DRE urine is associated with high grade group prostate cancer.
    Prostate. 2024 May 12. doi: 10.1002/pros.24724.
    >> Share

  225. ASHIDA S, Kawada C, Tanaka H, Kurabayashi A, et al
    Cutibacterium acnes invades prostate epithelial cells to induce BRCAness as a possible pathogen of prostate cancer.
    Prostate. 2024 May 9. doi: 10.1002/pros.24723.
    >> Share

  226. YIN J, Daryanani A, Lu F, Ku AT, et al
    Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis.
    Prostate. 2024 May 6. doi: 10.1002/pros.24718.
    >> Share

  227. HEETMAN JG, Paulino Pereira LJ, Kelder JC, Soeterik TFW, et al
    The additional value of (68)Ga-PSMA PET/CT SUVmax in predicting ISUP GG >/= 2 and ISUP GG >/= 3 prostate cancer in biopsy.
    Prostate. 2024 May 5. doi: 10.1002/pros.24716.
    >> Share

  228. QAZI SU, Altaf Z, Zafar M, Tariq MA, et al
    Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis.
    Prostate. 2024;84:525-538.
    >> Share

  229. ROMANO L, Napolitano L, Crocetto F, Sciorio C, et al
    Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms.
    Prostate. 2024;84:513-524.
    >> Share

  230. BERG FM, Correia ETO, Abenojar EC, Basilion JP, et al
    Multispecies comparative prostate anatomy by imaging: Implications for experimental models of prostatic disease.
    Prostate. 2024;84:682-693.
    >> Share

  231. SIMANEK V, Vrzakova R, Vitak R, Jirasko M, et al
    Preanalytical stability of molecular forms of prostate-specific antigen in serum samples (PSA, free PSA, [-2]proPSA) and their impact on fPSA/tPSA ratio and PHI.
    Prostate. 2024;84:656-665.
    >> Share

  232. KOSTECKA LG, Mendez S, Li M, Khare P, et al
    Cancer cells employ lipid droplets to survive toxic stress.
    Prostate. 2024;84:644-655.
    >> Share

    April 2024
  233. KARSH L, Du S, He J, Waters D, et al
    Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy.
    Prostate. 2024 Apr 29. doi: 10.1002/pros.24720.
    >> Share

  234. MIYAHIRA AK, Kamran SC, Jamaspishvili T, Marshall CH, et al
    Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2024 Apr 29. doi: 10.1002/pros.24721.
    >> Share

  235. NGUYEN AM, Carter GC, Wilson LM, Canfield S, et al
    Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene genomic prostate score(R) (GPS(TM)) assay.
    Prostate. 2024 Apr 26. doi: 10.1002/pros.24709.
    >> Share

  236. CHARLTON PV, O'Reilly D, Philippou Y, Rao SR, et al
    Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.
    Prostate. 2024 Apr 23. doi: 10.1002/pros.24715.
    >> Share

  237. KAREGAR-NIAVOL R, Ghaffari F, Saravi A, Fotokian Z, et al
    Translation and validation of a lifestyle questionnaire related to prostate cancer.
    Prostate. 2024 Apr 21. doi: 10.1002/pros.24713.
    >> Share

  238. MARSHALL CH, Gondek LP, Daniels V, Lu C, et al
    Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
    Prostate. 2024 Apr 20. doi: 10.1002/pros.24712.
    >> Share

  239. JIA T, Liu C, Guo P, Xu Y, et al
    FOXA1 regulates ribosomal RNA transcription in prostate cancer.
    Prostate. 2024 Apr 17. doi: 10.1002/pros.24714.
    >> Share

  240. ZHAO F, Zhao J, Wei X, Shi Y, et al
    Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.
    Prostate. 2024 Apr 17. doi: 10.1002/pros.24710.
    >> Share

  241. GRINDEDAL EM, Zucknick M, Stormorken A, Ronne E, et al
    Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome.
    Prostate. 2024 Apr 17. doi: 10.1002/pros.24711.
    >> Share

  242. CHAUDARY N, Wiljer E, Foltz W, Thapa P, et al
    An orthotopic prostate cancer model for new treatment development using syngeneic or patient-derived tumors.
    Prostate. 2024 Apr 12. doi: 10.1002/pros.24701.
    >> Share

  243. BROWN LK, Kanagasabai T, Li G, Celada SI, et al
    Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.
    Prostate. 2024 Apr 11. doi: 10.1002/pros.24706.
    >> Share

  244. MARTELIN N, De Witt B, Chen B, Eschwege P, et al
    Development and validation of an imageless machine-learning algorithm for the initial screening of prostate cancer.
    Prostate. 2024 Apr 4. doi: 10.1002/pros.24703.
    >> Share

  245. MODLIN IM, Kidd M, Drozdov IA, Boegemann M, et al
    Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.
    Prostate. 2024 Apr 3. doi: 10.1002/pros.24704.
    >> Share

  246. ALANAZI G, Alsubaie N, Nabi G, Gillingwater TH, et al
    Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy.
    Prostate. 2024;84:491-501.
    >> Share

  247. GEBRAEL G, Hage Chehade C, Sayegh N, Tripathi N, et al
    Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24696.
    >> Share

  248. KIM J, Park S, Kim S, Ryu S, et al
    Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24700.
    >> Share

  249. KU HC, Cheng E, Cheng CF
    A body shape index (ABSI) but not body mass index (BMI) is associated with prostate cancer-specific mortality: Evidence from the US NHANES database.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24698.
    >> Share

    March 2024
  250. SHAHAIT M, Hakansson AK, Daniel RE, Hosny K, et al
    Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer.
    Prostate. 2024 Mar 27. doi: 10.1002/pros.24684.
    >> Share

  251. MAHON KL, Sutherland SI, Lin HM, Stockler MR, et al
    Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
    Prostate. 2024 Mar 27. doi: 10.1002/pros.24691.
    >> Share

  252. DWINA Y, Zaid LSM, Saraswati M, Rachmadi L, et al
    CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration-resistant prostate cancer.
    Prostate. 2024 Mar 25. doi: 10.1002/pros.24690.
    >> Share

  253. ONAL C, Guler OC, Erbay G, Elmali A, et al
    The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer.
    Prostate. 2024 Mar 25. doi: 10.1002/pros.24693.
    >> Share

  254. DI BELLO F, Baudo A, de Angelis M, Jannello LMI, et al
    Other-cause mortality in incidental prostate cancer.
    Prostate. 2024 Mar 20. doi: 10.1002/pros.24689.
    >> Share

  255. HEERS H, Chwilka O, Huber J, Vogelmeier C, et al
    VOC-based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine-based approach.
    Prostate. 2024 Mar 18. doi: 10.1002/pros.24692.
    >> Share

  256. GU J, Chery L, Gonzalez GMN, Huff C, et al
    A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening.
    Prostate. 2024 Mar 13. doi: 10.1002/pros.24686.
    >> Share

  257. BRENNEN WN, Le Magnen C, Karkampouna S, Anselmino N, et al
    Defining the challenges and opportunities for using patient-derived models in prostate cancer research.
    Prostate. 2024 Mar 7. doi: 10.1002/pros.24682.
    >> Share

  258. HUANG H, Liu Z, Ma Y, Shao Y, et al
    Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
    Prostate. 2024;84:376-388.
    >> Share

    February 2024
  259. KAMADA S, Sakamoto S, Kinoshita R, Zhao X, et al
    Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
    Prostate. 2024 Feb 27. doi: 10.1002/pros.24679.
    >> Share

  260. YE PC, Leu WJ, Yeh TY, Hsu YT, et al
    A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
    Prostate. 2024 Feb 20. doi: 10.1002/pros.24678.
    >> Share

  261. LUO LS, Huang J, Luan HH, Mubarik S, et al
    Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS-plus, 1990-2019: A comparable study of key nations with emerging economies.
    Prostate. 2024 Feb 8. doi: 10.1002/pros.24673.
    >> Share

  262. ULYS A, Jankevicus F, Jievaltas M, Venckus R, et al
    Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial.
    Prostate. 2024 Feb 4. doi: 10.1002/pros.24674.
    >> Share

  263. HOYOS JA, Londono DR, Hoyos AG, Reyes EC, et al
    Impact of presentation timing in metastatic hormone-sensitive prostate cancer: Characterization of patients and identification of prognostic factors.
    Prostate. 2024 Feb 4. doi: 10.1002/pros.24672.
    >> Share

    January 2024
  264. PANACH-NAVARRETE J, Gonzalez-Marrachelli V, Morales-Tatay JM, Garcia-Morata F, et al
    Metabolic analysis using HR-MAS in prostate tissue for prostate cancer diagnosis.
    Prostate. 2024 Jan 11. doi: 10.1002/pros.24670.
    >> Share

  265. WHITE JA, Kaninjing ET, Adeniji KA, Jibrin P, et al
    Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
    Prostate. 2024 Jan 8. doi: 10.1002/pros.24662.
    >> Share

  266. DE KOUCHKOVSKY I, Chan E, Schloss C, Poehlein C, et al
    Diagnosis and management of neuroendocrine prostate cancer.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24664.
    >> Share

  267. ZHANG C, Tu X, Dai J, Zhang Z, et al
    Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real-world insights from a high-volume center in southwest China.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24669.
    >> Share

  268. OZAWA Y, Nohara S, Nakamura K, Hattori S, et al
    Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24668.
    >> Share

    December 2023
  269. MACKAY S, Oduor IO, Burch TC, Troyer DA, et al
    Prostate-specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma.
    Prostate. 2023 Dec 27. doi: 10.1002/pros.24666.
    >> Share

  270. PELLEGRINO F, Stabile A, Sorce G, Mazzone E, et al
    Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer.
    Prostate. 2023 Dec 27. doi: 10.1002/pros.24665.
    >> Share

  271. XIE H, Chen J, Ma Z, Gao Y, et al
    PrLZ regulates EMT and invasion in prostate cancer via the TGF-beta1/p-smad2/miR-200 family/ZEB1 axis.
    Prostate. 2023 Dec 25. doi: 10.1002/pros.24647.
    >> Share

  272. CANCEL M, Crottes D, Bellanger D, Bruyere F, et al
    Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors.
    Prostate. 2023 Dec 19. doi: 10.1002/pros.24655.
    >> Share

  273. D'AGOSTINO GR, Badalamenti M, Stefanini S, Baldaccini D, et al
    Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.
    Prostate. 2023 Dec 19. doi: 10.1002/pros.24657.
    >> Share

  274. LUKEZ A, Handorf E, Mendenhall NP, Henderson RH, et al
    A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
    Prostate. 2023 Dec 18. doi: 10.1002/pros.24660.
    >> Share

  275. MOON D, Hauck JS, Jiang X, Quang H, et al
    Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.
    Prostate. 2023 Dec 12. doi: 10.1002/pros.24654.
    >> Share

  276. ZENG J, Zhang Y, Xu R, Chen H, et al
    Nanomechanical-based classification of prostate tumor using atomic force microscopy.
    Prostate. 2023;83:1591-1601.
    >> Share

  277. BELUE MJ, Blake Z, Yilmaz EC, Lin Y, et al
    Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?
    Prostate. 2023;83:1519-1528.
    >> Share

  278. RAVI P, Kwak L, Devlies W, Xie W, et al
    Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer.
    Prostate. 2023 Dec 1. doi: 10.1002/pros.24653.
    >> Share

    November 2023
  279. AL SHAREEF Z, Al-Shahrabi R, Saheb Sharif-Askari F, AlDhmanie A, et al
    Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
    Prostate. 2023 Nov 15:e24637. doi: 10.1002/pros.24637.
    >> Share

  280. PALLER CJ, Barata PC, Lorentz J, Appleman LJ, et al
    PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
    Prostate. 2023 Nov 14. doi: 10.1002/pros.24650.
    >> Share

  281. MULLEN SA, Das D, Ziamiavaghi N, High R, et al
    Association of plasma NRP2 and VEGF-C levels with prostate cancer disease severity.
    Prostate. 2023 Nov 9. doi: 10.1002/pros.24648.
    >> Share

  282. LI J, Wang K, Li S, Wu P, et al
    Clinical study of multifactorial diagnosis in prostate biopsy.
    Prostate. 2023;83:1494-1503.
    >> Share

  283. MIYAHIRA AK, Soule HR
    The 29th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2023 Nov 1:e24640. doi: 10.1002/pros.24640.
    >> Share

  284. GOVINDAN S, Cheranda N, Riekhof F, Luo S, et al
    Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Prostate. 2023 Nov 1. doi: 10.1002/pros.24644.
    >> Share

    October 2023
  285. ALSAIDAN OA, Onobun E, Ye C, Lou L, et al
    Inhibition of N-myristoyltransferase activity promotes androgen receptor degradation in prostate cancer.
    Prostate. 2023 Oct 31. doi: 10.1002/pros.24645.
    >> Share

  286. DI H, Wen Y
    Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis.
    Prostate. 2023 Oct 31. doi: 10.1002/pros.24646.
    >> Share

  287. FU W, Xu L, Chen Y, Zhang Z, et al
    Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy.
    Prostate. 2023 Oct 30. doi: 10.1002/pros.24642.
    >> Share

  288. MAHMOUD AM, Childs DS, Ahmed ME, Tuba Kendi A, et al
    Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis.
    Prostate. 2023 Oct 29. doi: 10.1002/pros.24643.
    >> Share

  289. ECHEVERRIA CE, Oyarzun VI, Lopez-Cortes A, Cancino J, et al
    Biological role of fructose in the male reproductive system: Potential implications for prostate cancer.
    Prostate. 2023 Oct 27. doi: 10.1002/pros.24631.
    >> Share

  290. HU HP, Anagnostopoulos G, Gouran-Savadkoohi M, Dayes I, et al
    Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
    Prostate. 2023 Oct 25. doi: 10.1002/pros.24638.
    >> Share

  291. MITCHELL AP, Persaud S, Palyca P, Salner A, et al
    Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
    Prostate. 2023 Oct 16. doi: 10.1002/pros.24636.
    >> Share

  292. SIEGELMANN-DANIELI N, Neiman V, Bareket-Samish A, Berger R, et al
    Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
    Prostate. 2023 Oct 16. doi: 10.1002/pros.24622.
    >> Share

  293. MENEZES RDS, Dornas MC, Campos CFF, Rodeiro DB, et al
    Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ.
    Prostate. 2023 Oct 15. doi: 10.1002/pros.24635.
    >> Share

  294. PEDRAZA AM, Gupta R, Musheyev D, Pino T, et al
    Microultrasound in the detection of the index lesion in prostate cancer.
    Prostate. 2023 Oct 12. doi: 10.1002/pros.24628.
    >> Share

  295. WANG L, Lyu C, Stadlbauer B, Buchner A, et al
    Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p-STAT3 in prostate cancer.
    Prostate. 2023 Oct 12. doi: 10.1002/pros.24632.
    >> Share

  296. HOANG T, Sutera P, Nguyen T, Chang J, et al
    TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
    Prostate. 2023 Oct 9. doi: 10.1002/pros.24629.
    >> Share

  297. LABRECQUE MP, Brown LG, Coleman IM, Nguyen HM, et al
    Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
    Prostate. 2023 Oct 5. doi: 10.1002/pros.24630.
    >> Share

    September 2023
  298. ARAFA MA, Farhat KH, Khan FK, Rabah DM, et al
    Development and internal validation of a nomogram predicting significant prostate cancer: Is it clinically applicable in low prevalent prostate cancer countries? A multicenter study.
    Prostate. 2023 Sep 27. doi: 10.1002/pros.24625.
    >> Share

  299. RAJWA P, Heidenreich J, Drzezga A, Schmidt M, et al
    The diagnostic accuracy of (68) Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis.
    Prostate. 2023 Sep 26. doi: 10.1002/pros.24627.
    >> Share

  300. ZOU P, Chen Z, He Q, Zhuo Y, et al
    Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis.
    Prostate. 2023 Sep 26. doi: 10.1002/pros.24626.
    >> Share

  301. KOELKER M, Labban M, Frego N, Ye J, et al
    Racial differences in patient-reported outcomes among men treated with radical prostatectomy for prostate cancer.
    Prostate. 2023 Sep 14. doi: 10.1002/pros.24624.
    >> Share

  302. ULERI A, Baboudjian M, Tedde A, Rajwa P, et al
    The association between beta-blockers use and prostate cancer mortality: A mini systematic review and meta-analysis.
    Prostate. 2023 Sep 14. doi: 10.1002/pros.24623.
    >> Share

  303. YAMADA Y, Sakamoto S, Sato K, Saito S, et al
    Clinical utility of the prognostic nutritional index in patients with metastatic hormone-sensitive prostate cancer: A retrospective, multicenter, cohort study.
    Prostate. 2023 Sep 10. doi: 10.1002/pros.24619.
    >> Share

  304. ESEN B, Seymen H, Gurses B, Armutlu A, et al
    The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer.
    Prostate. 2023 Sep 3. doi: 10.1002/pros.24621.
    >> Share

  305. FUJIWARA S, Kosaka T, Nishimoto Y, Kamisawa K, et al
    Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel.
    Prostate. 2023 Sep 3. doi: 10.1002/pros.24620.
    >> Share

  306. FRANCOLINI G, Banini M, Di Cataldo V, Detti B, et al
    PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study.
    Prostate. 2023;83:1201-1206.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016